Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: effects of peroxisome proliferator-activated receptor agonists
- 82 Downloads
High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARα γ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8±5.9 g, p<0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23%, p<0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r=0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARα γ activator (LM 4156).
KeywordsMagnetic resonance imaging (MRI) Fat remodeling Diabetes Adipose tissues Peroxisome proliferator-activated receptor (PPAR)
Unable to display preview. Download preview PDF.
- 3.Changani KK, Nicholson A, White A, Latchman JK, Reid DG, Clapham JC (2003) A longitudinal magnetic resonance imaging (MRI) study of differences in abdominal fat distribution between normal mice, and lean overexpressors of mitochondrial uncoupling protein-3 (UCP-3). Diabetes Obes Metab 5:99–105CrossRefPubMedGoogle Scholar
- 4.Tang H, Vasselli JR, Wu EX (2002) High-resolution magnetic resonance imaging tracks changes in organ and tissue mass in obese and aging rats. Am J Physiol Regul Comp Physiol 282:R890–R899Google Scholar
- 5.Kenneth JE (2000) Human body composition: in vivo methods. Physiol Rev 2:649–680Google Scholar
- 22.Chevreuil O, Contard F, Guerrier D (2003) LM 4156, a novel, balanced activator of PPAR alpha and gamma improves dyslipidemia in fa/fa Zucker Rats. Diabetes 52(Suppl. 6):A114Google Scholar
- 23.Contard F, Chevreuil O, Guerrier D (2003) LM 4156, a novel, balanced PPAR α and γ activator decreases hypertriglyceridaemia without effects on body weight and adipose tissue in fa/fa Zucker Rats. Diabetes 52(Suppl. 1):A444Google Scholar
- 27.Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein EH, Smith SA, Cobitz AR, Susanta K Sarkar (2003) Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism 52:218–225CrossRefPubMedGoogle Scholar
- 29.Lebovitz HE (1997) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18(Suppl. 2):S23–S29Google Scholar
- 34.Lebovitz HE (1997) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18(Suppl. 2):S23–S29Google Scholar